Skip to main content

Table 3 Indicators for quantity and quality of antibiotic use in surgery patients

From: A comprehensive point prevalence survey of the quality and quantity of antimicrobial use in Chinese general hospitals and clinical specialties

Items

GenS

Urol

NeuroS

Gyn

HepaB

Ortho

GiS

OncoS

Others

Total

Prescriptions (n)

369

645

431

511

327

185

418

26

77

2989

Antibiotics use rate (%)

31.59

50.98

21.62

23.95

45.34

22.14

36.17

15.94

18.68

31.91

Surgical type (%)

Clean

9.52

23.37

64.29

22.92

16.09

69.48

14.22

 

40.91

31.29

Contaminated

29.25

37.38

8.65

68.06

48.85

10.39

62.84

77.78

25.00

39.57

Infected

7.48

0.62

1.13

1.74

8.62

9.74

1.83

 

4.55

3.50

Unknown

53.74

38.63

25.94

7.29

26.44

10.39

21.10

22.22

29.55

25.64

Antibiotics use purpose (%)

Therapeutics

52.57

55.19

43.62

25.05

43.73

11.35

35.41

26.92

57.14

41.12

Prophylaxis

26.02

32.25

51.04

74.17

51.07

81.62

60.77

73.08

23.38

50.59

Unknown

21.41

12.56

5.34

0.78

5.20

7.03

3.83

 

19.48

8.30

Therapeutics (%)

Empiric

85.35

87.19

61.14

89.39

93.75

50.00

87.81

85.70

89.83

83.34

Targeted

2.57

7.78

33.65

6.08

3.13

38.25

6.092

14.30

3.39

10.22

Unknown

12.08

5.03

5.21

4.53

3.13

11.75

6.09

 

6.77

6.44

Surgical prophylaxis (%)

57.14

59.50

76.69

95.14

76.44

95.45

83.49

94.44

38.64

76.63

AUI (DDDs/100 patient.day)

43.82

73.67

31.42

43.23

67.68

27.70

62.79

40.19

23.74

45.81

Guidelines(%)

Complied

73.71

78.14

83.29

82.78

81.96

90.81

77.03

100

76.62

80.33

Non-complied

9.49

15.50

10.90

11.15

11.62

4.32

12.44

 

3.90

11.38

Unavailable

6.50

1.86

0.93

 

0.92

 

6.22

 

14.29

2.68

No guideline

1.36

0.62

0.93

 

0.92

1.08

  

1.30

0.64

Unknown

8.94

3.88

3.94

6.07

4.59

3.78

4.31

 

3.90

4.98

Therapy referring to biomarkers (%)

28.46

40.00

20.42

14.48

21.10

2.16

19.38

23.08

46.75

24.12

Prescription reason recorded (%)

29.81

17.36

6.73

7.83

14.98

2.16

10.29

23.08

40.26

14.19

Therapeutic duration up to PPS (d)

 ≤ 3

32.96

33.15

23.69

52.26

38.12

29.43

29.88

71.43

38.98

36.89

4–7

33.33

42.95

21.32

34.84

24.99

32.37

35.34

28.57

38.98

32.23

8–14

13.19

17.99

22.75

10.61

27.51

11.75

21.95

 

13.56

17.40

 ≥ 15

18.31

2.68

27.96

1.51

6.25

17.63

9.15

 

5.09

10.50

Unknown

2.20

3.22

4.27

0.77

3.13

8.81

3.67

 

3.39

2.97

Administrative route (%)

Intravenous

96.00

94.20

93.54

83.71

97.48

91.27

97.14

97.37

95.38

93.66

Oral

1.23

3.48

1.90

16.01

0.31

5.56

1.04

 

1.54

4.04

Others

 

0.34

   

0.79

 

2.63

 

0.16

Unknown

2.77

1.99

4.56

0.28

2.20

2.38

1.82

 

3.08

2.14

Combinatory use (%)

Single

63.84

74.95

76.56

40.21

64.65

58.62

41.79

36.36

78.43

63.05

2 drugs

29.91

21.63

21.53

46.91

27.91

39.08

40.30

59.09

17.65

30.00

 ≥ 3 drugs

6.25

3.43

1.92

12.88

7.45

2.30

17.92

4.55

3.92

6.94

Stop or review recorded (%)

58.27

39.84

19.72

16.83

25.08

5.95

16.99

23.08

61.04

44.94

  1. GenS General surgery; Urol Urology; NeurS Neurosurgery; Gyn Gynecology; HepaB Hepatobiliary surgery; Orth Orthopedics; GiS Gastrointestinal surgery; OncoS Oncological surgery; RTI Respiratory tract infection; NA Non-applicable; FUO Fever unknown origin; GI/IAI Gastroenterological infection and intra-abdominal infection; SST&BJ Skin and skin structure, and bone and joint infections; UTI urinary tract infection; GUM Male genital infection; CNS Central nerve system infection; GY Ynecological infection; AUI Antibiotic use intensity